重組 DNA 技術市場規模、佔有率和成長分析（按產品、組件、應用、最終用途和地區）- 產業預測 2025-2032

預計2023年全球重組 DNA 技術市場規模將達到 1,555 億美元，並從 2024 年的 1,671.6 億美元成長到 2032 年的 2,981.3 億美元，預測期內（2025-2032 年）的複合年成長率為 7.5%。

重組 DNA（rDNA）技術徹底改變了基因資料管理，實現了生物技術和製藥領域的多種應用。最近的進展使得生產重組藥物不再需要人類捐贈者，例如用於糖尿病管理的基因改造胰島素的商業性成功。隨著慢性病成本的上升，業界正在利用 rDNA 技術尋找創新治療方案。特別是，正在開發使用 CRISPR/Cas9、ZFN 和 TALEN 技術的重組蛋白，以增強生物製藥的進步和精準基因組編輯。此外，全球基改作物面積的不斷擴大，證實了rDNA在農業領域的成功，其應用範圍也擴展到生質燃料和應對環境挑戰的生物農藥。然而，關於基因治療及其技術的使用的倫理問題在許多領域一直存在爭議。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

重組 DNA 技術市場規模（按產品和複合年成長率） (2025-2032)

• 市場概況
• 醫療
  • 治療
  • 人類蛋白質
  • 疫苗
• 非醫療
  • 生物技術作物
  • 特種化學品
  • 其他非醫療產品

重組 DNA 技術市場規模（按組件和複合年成長率） (2025-2032)

• 市場概況
• 表達系統
  • 哺乳類
  • 細菌
  • 酵母菌
  • 桿狀病毒/昆蟲
  • 其他表達系統
• 克隆載體

重組 DNA 技術市場規模（按應用分類）及複合年成長率（2025-2032）

• 市場概況
• 食品和農業
• 健康與疾病
  • 人類
  • 動物
• 環境
• 其他用途

重組 DNA 技術市場規模（按最終用途和複合年成長率分類）（2025-2032 年）

• 市場概況
• 生技及製藥公司
• 學術和政府研究組織
• 其他最終用途

重組 DNA 技術市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司詳細資訊
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Thermo Fisher Scientific（US）
• Roche Holding AG（Switzerland）
• Merck KGaA（Germany）
• Agilent Technologies（US）
• Bio-Rad Laboratories（US）
• Illumina（US）
• Danaher Corporation（US）
• Sartorius AG（Germany）
• Lonza Group（Switzerland）
• Charles River Laboratories（US）
• GenScript Biotech Corporation（China）
• Twist Bioscience（US）
• Ginkgo Bioworks（US）
• Amyris（US）
• Synthetic Genomics（US）
• Intrexon（US）
• PerkinElmer（US）
• Eurofins Scientific（Luxembourg）

結論和建議

Global Recombinant DNA Technology Market size was valued at USD 155.5 billion in 2023 and is poised to grow from USD 167.16 billion in 2024 to USD 298.13 billion by 2032, growing at a CAGR of 7.5% during the forecast period (2025-2032).

Recombinant DNA (rDNA) technology has transformed genetic data control, allowing for various applications across the biotech and pharmaceutical landscapes. Recent advancements have enabled the successful production of recombinant medications without human donors, highlighted by the commercial success of genetically modified insulin for diabetes management. As chronic disease costs rise, the industry is leveraging rDNA methods for innovative therapeutic solutions. The ongoing development of recombinant proteins, particularly using CRISPR/Cas9, ZFN, and TALEN technologies, enhances biopharmaceutical advancements and precision genome editing. Additionally, the global expansion of GM crop acreage underscores rDNA's success in agriculture, with applications extending to biofuels and biopesticides for environmental challenges. However, ethical concerns regarding gene therapy and technology usage present ongoing debates across various sectors.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Recombinant Dna Technology market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Recombinant Dna Technology Market Segments Analysis

Global Recombinant DNA Technology Market is segmented by Product, Component, Application, End Use and region. Based on Product, the market is segmented into Medical and Non-medical. Based on Component, the market is segmented into Expression System and Cloning Vector. Based on Application, the market is segmented into Food & Agriculture, Health & Disease, Environment and Other Applications. Based on End Use, the market is segmented into Biotechnology and Pharmaceutical Companies, Academic & Government Research Institutes and Other End Uses. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Recombinant Dna Technology Market

The growth of the global recombinant DNA technology market during the forecast period is anticipated to be significantly influenced by an increase in strategic partnerships among major industry players. These collaborations aim to advance the development of recombinant DNA technologies and often involve partnerships with prominent biopharmaceutical companies and research institutions to create innovative therapeutics. Such collective efforts and strategic alliances within the market are expected to facilitate advancements and drive expansion in the sector, leading to new opportunities and a heightened competitive landscape in the field of recombinant DNA technology.

Restraints in the Global Recombinant Dna Technology Market

The growth of the Global Recombinant DNA Technology market is being hindered by several factors, primarily the high costs associated with gene therapy. Additionally, potential side effects, such as Cytokine Release Syndrome (CRS) and neurotoxicity, pose significant challenges. The anticipated expansion of the market is further limited by various ethical, legal, and scientific constraints surrounding gene therapy applications. These restrictions not only impact research and development efforts but also contribute to hesitation among stakeholders, ultimately affecting the overall progress and acceptance of recombinant DNA technologies within the healthcare landscape.

Market Trends of the Global Recombinant Dna Technology Market

The Global Recombinant DNA Technology market is witnessing a significant upward trend driven by increasing public acceptance of genetically modified crops aimed at enhancing agricultural yield and pest resistance. Pioneering initiatives, such as the licensing of the genetically modified tomato CGN-89564-2 for human consumption, are paving the way for broader applications across various sectors. The intersection of DNA molecular marker technologies further facilitates the identification and innovation of valuable plant germplasm resources. This surge in research and application of GMOs, particularly in food, agriculture, and medicine, underscores the potential of recombinant DNA technology to revolutionize health care and biomedicine, creating lucrative opportunities for market stakeholders.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Recombinant DNA Technology Market Size by Product & CAGR (2025-2032)

• Market Overview
• Medical
  • Therapeutic Agent
  • Human Protein
  • Vaccine
• Non-medical
  • Biotech Crops
  • Specialty Chemicals
  • Other Non-medical Products

Global Recombinant DNA Technology Market Size by Component & CAGR (2025-2032)

• Market Overview
• Expression System
  • Mammalian
  • Bacteria
  • Yeast
  • Baculovirus / Insect
  • Other Expression Systems
• Cloning Vector

Global Recombinant DNA Technology Market Size by Application & CAGR (2025-2032)

• Market Overview
• Food & Agriculture
• Health & Disease
  • Human
  • Animal
• Environment
• Other Applications

Global Recombinant DNA Technology Market Size by End Use & CAGR (2025-2032)

• Market Overview
• Biotechnology and Pharmaceutical Companies
• Academic & Government Research Institutes
• Other End Uses

Global Recombinant DNA Technology Market Size & CAGR (2025-2032)

• North America (Product, Component, Application, End Use)
  • US
  • Canada
• Europe (Product, Component, Application, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Component, Application, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Component, Application, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Component, Application, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Thermo Fisher Scientific (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sartorius AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza Group (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GenScript Biotech Corporation (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Twist Bioscience (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ginkgo Bioworks (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amyris (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Synthetic Genomics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intrexon (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific (Luxembourg)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations